Genitourinary Cancers Symposium (ASCO GU) | Conference

ASCO GU 2021 News: Dr. Petros Grivas and Dr. Arlene Siefker-Radtke

February 15th 2021

Cabozantinib Significantly Prolongs PFS Over Sunitinib in Papillary RCC

February 14th 2021

February 13, 2021 - Cabozantinib resulted in a statistically significant and clinically meaningful prolongation of progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma.

Lenvatinib Plus Pembrolizumab Improves Survival, Responses Versus Sunitinib in Advanced RCC

February 13th 2021

February 13, 2021 - Lenvatinib in combination with pembrolizumab resulted in improved overall survival, progression-free survival, and objective response rate over sunitinib in the frontline treatment of patients with advanced renal cell carcinoma.

Belzutifan/Cabozantinib Shows Promising Early Antitumor Activity in Advanced Clear Cell RCC

February 13th 2021

February 13, 2021 - Belzutifan used in combination with cabozantinib shrank tumors for 88% of patients and the disease control rate was 90% for patients with previously treated advanced clear cell renal cell carcinoma.

Molecular Signatures Linked With Long-Term Response to Apalutamide in Nonmetastatic CRPC

February 13th 2021

February 13, 2021 - Certain molecular signatures at baseline were found to be independently linked with long-term response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

BCG Plus N-803 Elicits Positive Responses, Tolerability in BCG-Unresponsive NMIBC CIS

February 13th 2021

February 13, 2021 - Bacillus calmette-guérin plus N-803 demonstrated promising responses with a tolerable safety profile when used in patients with BCG-unresponsive, non–muscle-invasive bladder cancer carcinoma in situ

Reduction in PSA Screening Associated with Increased Incidence of Metastatic Prostate Cancer in the United States

February 13th 2021

February 13, 2021 - Reductions in prostate-specific antigen screening are likely responsible for the recent increase in metastatic prostate cancer cases in the United States.

PSMA PET Imaging Agent 18F-DCFPyL Demonstrates High CLR and PPV

February 13th 2021

February 13, 2021 - 18F-DCFPyL, an investigational prostate-specific membrane antigen PET imaging agent, was found to detect and localize metastatic lesions with a high correct localization rate and positive predictive value.

ASCO GU 2021 News: Drs. Bradley McGregor, David Braun, and

February 13th 2021

Dr. Piliè on Impact of Adiposity on Response to Androgen Signaling Inhibition in mCRPC

February 13th 2021

Patrick Pilie, MD, discusses the impact of adiposity on response to androgen signaling inhibition in patients with metastatic castration-resistant prostate cancer.